Colorectal Carcinoma metastatic | Standard therapy failed | Fluorouracil | irinotecan | oxaliplatin | Vascular Endothelial Growth Factor Receptor Inhibitors | Anti-epidermal growth factor receptor | Neoplasms RAS Wild Type
Item
1. metastatic colorectal cancer and failure to standard therapies (5-fluorouracil, irinotecan, oxaliplatin, anti-vascular endothelium growth factor, anti-epidermal growth factors in patients with ras wild type tumors). a previous line with regorafenib is not required.
boolean
C0009402 (UMLS CUI [1,1])
C1522484 (UMLS CUI [1,2])
C2936643 (UMLS CUI [2,1])
C0231175 (UMLS CUI [2,2])
C0016360 (UMLS CUI [3])
C0123931 (UMLS CUI [4])
C0069717 (UMLS CUI [5])
C2267120 (UMLS CUI [6])
C4055105 (UMLS CUI [7])
C0027651 (UMLS CUI [8,1])
C4331207 (UMLS CUI [8,2])
Elevated CEA | CEA Expression Tumor tissue sample
Item
2. elevated cea serum level or proved cea expression in tumor tissue
boolean
C0742014 (UMLS CUI [1])
C0007082 (UMLS CUI [2,1])
C0017262 (UMLS CUI [2,2])
C0475358 (UMLS CUI [2,3])
Age
Item
3. ≥ 18 years of age,
boolean
C0001779 (UMLS CUI [1])
Informed Consent
Item
4. given signed, written informed consent
boolean
C0021430 (UMLS CUI [1])
Neoplasm Measurable lesion Quantity CT | Neoplasm Measurable lesion Quantity MRI | Lesion Diameter
Item
5. existence of at least one measurable tumor lesion by ct or mri at the time of treatment, but no single lesion ≥ 8 cm in diameter.
boolean
C0027651 (UMLS CUI [1,1])
C1513041 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0040405 (UMLS CUI [1,4])
C0027651 (UMLS CUI [2,1])
C1513041 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C0024485 (UMLS CUI [2,4])
C0221198 (UMLS CUI [3,1])
C1301886 (UMLS CUI [3,2])
Recovery Time period | Status post Major surgery | Status post Therapeutic radiology procedure | Status post Chemotherapy | Toxicity Due to Prior Therapy | Patient recovered
Item
6. at least 4 weeks recovery period after any major surgery, radiation, or chemotherapy, and total recovery from any acute toxicities associated with these prior treatments.
boolean
C2004454 (UMLS CUI [1,1])
C1948053 (UMLS CUI [1,2])
C0231290 (UMLS CUI [2,1])
C0679637 (UMLS CUI [2,2])
C0231290 (UMLS CUI [3,1])
C1522449 (UMLS CUI [3,2])
C0231290 (UMLS CUI [4,1])
C0392920 (UMLS CUI [4,2])
C0600688 (UMLS CUI [5,1])
C0678226 (UMLS CUI [5,2])
C1514463 (UMLS CUI [5,3])
C1115804 (UMLS CUI [6])
Life Expectancy | Karnofsky Performance Status
Item
7. life expectancy ≥ 3 months, karnofsky performance status of ≥ 70%
boolean
C0023671 (UMLS CUI [1])
C0206065 (UMLS CUI [2])
Hematologic function | Renal function | Liver function
Item
8. adequate hematology and renal function and hepatic function
boolean
C0221130 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
Childbearing Potential Contraceptive methods | Childbearing Potential Serum pregnancy test negative
Item
9. patients of childbearing potential must be willing to practice birth control during the study until at least 12 weeks after treatment, and women of childbearing potential must have a negative serum pregnancy test to enter the study
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C3831118 (UMLS CUI [2,1])
C0430061 (UMLS CUI [2,2])
Exclusion Criteria
Item
exclusion criteria :
boolean
C0680251 (UMLS CUI [1])
CNS metastases
Item
1. known central nervous system metastatic disease
boolean
C0686377 (UMLS CUI [1])
Bone Marrow Involvement Percentage
Item
2. > 25% bone marrow involvement
boolean
C1517677 (UMLS CUI [1,1])
C0439165 (UMLS CUI [1,2])
CEA measurement Plasma
Item
3. cea plasma levels >2,000 ng/ml
boolean
C0201933 (UMLS CUI [1,1])
C0032105 (UMLS CUI [1,2])
Eligibility Skin carcinoma Treated | Eligibility Carcinoma in situ of uterine cervix Treated | Eligibility Cancer Other Disease Free
Item
4. patients with successfully treated non-melanoma skin cancer or carcinoma in situ of the cervix are eligible, while patients with other prior malignancies must have had at least a 3-year disease-free interval.
boolean
C1548635 (UMLS CUI [1,1])
C0699893 (UMLS CUI [1,2])
C1522326 (UMLS CUI [1,3])
C1548635 (UMLS CUI [2,1])
C0851140 (UMLS CUI [2,2])
C1522326 (UMLS CUI [2,3])
C1548635 (UMLS CUI [3,1])
C1707251 (UMLS CUI [3,2])
C0012634 (UMLS CUI [3,3])
C0332296 (UMLS CUI [3,4])
HIV Seropositivity | Hepatitis B antigen positive | Hepatitis C positive
Item
5. hiv positive, hepatitis b-antigen positive, or hepatitis c positive patients
boolean
C0019699 (UMLS CUI [1])
C1504344 (UMLS CUI [2])
C1112419 (UMLS CUI [3])
Autoimmune Disease
Item
6. known autoimmune disease,
boolean
C0004364 (UMLS CUI [1])
Angina, Unstable | Myocardial Infarction | Congestive heart failure | Cardiac Arrhythmia | Exception Atrial Fibrillation Stable | Requirement Anti-Arrhythmia Agents | Chronic Obstructive Airway Disease Absent | Chronic disease of respiratory system Moderate Absent | Chronic disease of respiratory system Severe Absent
Item
7. known history of unstable angina, myocardial infarction, or congestive heart failure present within 6 months or clinically significant cardiac arrhythmia (other than stable atrial fibrillation) requiring anti-arrhythmia therapy, no known history of clinical significant, active chronic obstructive pulmonary disease, or other moderate to severe chronic respiratory illness present within 6 months
boolean
C0002965 (UMLS CUI [1])
C0027051 (UMLS CUI [2])
C0018802 (UMLS CUI [3])
C0003811 (UMLS CUI [4])
C1705847 (UMLS CUI [5,1])
C0004238 (UMLS CUI [5,2])
C0205360 (UMLS CUI [5,3])
C1514873 (UMLS CUI [6,1])
C0003195 (UMLS CUI [6,2])
C0024117 (UMLS CUI [7,1])
C0332197 (UMLS CUI [7,2])
C0264220 (UMLS CUI [8,1])
C0205081 (UMLS CUI [8,2])
C0332197 (UMLS CUI [8,3])
C0264220 (UMLS CUI [9,1])
C0205082 (UMLS CUI [9,2])
C0332197 (UMLS CUI [9,3])
Communicable Disease | Requirement Antibiotics Intravenous
Item
8. infection requiring intravenous antibiotic use within 1 week before inclusion,
boolean
C0009450 (UMLS CUI [1])
C1514873 (UMLS CUI [2,1])
C0003232 (UMLS CUI [2,2])
C1522726 (UMLS CUI [2,3])
Adrenal Cortex Hormones | Exception Low-Dose Treatment Nausea | Exception Low-Dose Treatment Rheumatoid Arthritis
Item
9. corticosteroids are not allowed within 2 weeks of study entry nor during the study except low doses (i.e., 20 mg/day of prednisone or equivalent) to treat nausea or other illness such as rheumatoid arthritis.
boolean
C0001617 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C1708745 (UMLS CUI [2,2])
C0027497 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C1708745 (UMLS CUI [3,2])
C0003873 (UMLS CUI [3,3])
Therapeutic procedure Containing Nitrosourea Compounds
Item
10. patients who received a treatment containing a nitrosourea compound will not be enrolled for at least 6 weeks after the end of that treatment.
boolean
C0087111 (UMLS CUI [1,1])
C0332256 (UMLS CUI [1,2])
C0028210 (UMLS CUI [1,3])
Hypersensitivity Murine-Derived Monoclonal Antibodies | Hypersensitivity Murine protein
Item
11. known hypersensitivity to murine antibodies or proteins
boolean
C0020517 (UMLS CUI [1,1])
C2916903 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C1699668 (UMLS CUI [2,2])
Immunization Against TF2 | TF2 Injection
Item
12. immunization against tf2 for patients who has already received injection of tf2
boolean
C0020971 (UMLS CUI [1,1])
C0521124 (UMLS CUI [1,2])
C2826117 (UMLS CUI [1,3])
C2826117 (UMLS CUI [2,1])
C1828121 (UMLS CUI [2,2])
Adult | Informed Consent Unable | Mental impairment
Item
13. adult patient unable to give informed consent because of intellectual impairment.
boolean
C0001675 (UMLS CUI [1])
C0021430 (UMLS CUI [2,1])
C1299582 (UMLS CUI [2,2])
C0683322 (UMLS CUI [3])
Adult | Protection of patient Law
Item
14. adult patient protected by the french law
boolean
C0001675 (UMLS CUI [1])
C0412786 (UMLS CUI [2,1])
C0220866 (UMLS CUI [2,2])